Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Nab-Xelpac
Beacon Pharmaceuticals PLC
Generic: Nanoparticle Albumin-Bound (NAB) Paclitaxel
Medicine Overview of Nab-Xelpac 100mg/vial Injection
বাংলা
English
Indication
Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma of the Pancreas
Administration
IV Preparation Aseptically reconstitute vial by slowly injecting 20 mL 0.9% NaCl over 1 min by allowing fluid to fall down inside wall of tube (this will avoid foaming) Swirl or invert to mix (do not shake) Resulting reconstituted suspension should be milky and homogenous without visible particulates Resulting solution is 5 mg/mL If foaming occurs stand solution for at least 15 min until foaming subsides Inject the appropriate amount of reconstituted suspension into an empty, sterile IV bag (PVC containers, PVC or non-PVC type IV bag) The use of specialized DEHP-free solution containers or administration sets is not necessary...
... Show moreAdult Dose
Pancreatic Cancer Indicated for metastatic adenocarcinoma of the pancreas as first-line treatment in combination with gemcitabine 125 mg/m² IV infused over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle Administer gemcitabine 1000 mg/m² IV infused over 30-40 minutes immediately after paclitaxel protein bound on Days 1, 8 and 15 of each 28-day cycle Dosage modifications (pancreatic cancer) 1st dose reduction: 100 mg/m² (paclitaxel); 800 mg/m² (gemcitabine) 2nd dose reduction: 75 mg/m² (paclitaxel); 600 mg/m² (gemcitabine) Discontinue if additional dose reduction required Dosage modifications (pancreatic cancer – hematologic toxicities) Cycle Day 1: ANC 1000/mm³ or platelets ?75,000/mm³...
... Show moreContraindication
Neutrophils <1500 cells/mm³
Severe and sometimes fatal hypersensitivity reactions, including anaphylactic reactions reported; do not rechallenge in patients who experience severe hypersensitivity
Mode of Action
Microtubular inhibitor (albumin-conjugated formulation); natural taxane, prevents depolymerization of cellular microtubules, which results in DNA, RNA, and protein synthesis inhibition
Precaution
Causes myelosuppression; monitor CBC and withhold and/or reduce the dose as needed (see Dosage Modifications) Sensory neuropathy occurs frequently and may require dose reduction or treatment interruption (see Dosage Modifications) Sepsis occurred in 5% of patients with or without neutropenia; biliary obstruction or presence of biliary stent were risk factors for severe or fatal sepsis Pneumonitis, including fatalities, occurred in 4% of patients Exposure and toxicity increased with hepatic impairment; particularly from myelosuppression; closely monitor for development of profound myelosuppression; monitor AST and bilirubin and adjust dose if needed (see Dosage Modifications) Contains albumin derived from human blood which has...
... Show moreSide Effect
>10%
Alopecia (90%)
Neutropenia (<2 x 10^9/L) (80%)
Sensory neuropathy, any (71%)
Abnormal EKG, all patients (60%)
Asthenia (47%)
Myalgia/arthralgia (44%)
AST increased (39%)
Alkaline phosphatase increased (36%)
Abnormal EKG, patients normal at baseline (35%)
Anemia (<11 g/dL) (33%)
Nausea (30%)
Diarrhea (27%)
Infections (24%)
Vomiting (18%)
Dyspnea (12%)
Neutropenia (grade 3-4)
NSCLC (47%)
Pancreatic cancer (38%)
Metastatic breast cancer (34%)
1-10%
Sensory neuropathy, severe (10%)
Edema (10%)
Neutropenia (<0.5 x 10^9/L) (9%)
Cough (7%)
Mucositis (7%)
Bilirubin increased (7%)
Hypotension, during infusion (5%)
Hypersensitivity reactions (4%)
Thrombocytopenia (2%)
Febrile neutropenia (2%)
Bleeding (2%)
Anemia (<8 g/dL) (1%)
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register